# Executive Summary: Lithium and Alzheimer's Disease Prevention

## Bottom Line Up Front

**A landmark 2025 study in *Nature* provides strong evidence that lithium deficiency may contribute to Alzheimer's disease, and that lithium replacement therapy—particularly with lithium orotate—could be a potential prevention and treatment approach.**

---

## Key Takeaways

### ✅ What the Science Shows

1. **Lithium is the only metal** significantly reduced in the brains of people with early cognitive impairment
2. **Amyloid plaques trap lithium**, reducing its availability to healthy brain tissue
3. **Lithium orotate** (not the traditional lithium carbonate) can bypass this trapping mechanism
4. In mice, lithium orotate **reversed memory loss** and **prevented cognitive decline**
5. Population studies show **17% reduced dementia risk** with higher natural lithium exposure
6. Meta-analyses of clinical trials show **statistically significant cognitive benefits**

### ⚠️ What We Don't Know Yet

1. **Optimal dose** for humans
2. **Long-term safety** of lithium orotate specifically
3. Whether benefits seen in mice **translate to humans**
4. How lithium orotate compares to carbonate **in human trials**

---

## Should People Take Lithium Orotate Now?

### Official Recommendation: **NO** (Not Yet)

**From Dr. Bruce Yankner (Study Author):**
> "Before recommending lithium orotate, we need to determine the effective and safe dose range in people. We are planning a clinical trial of lithium orotate that will hopefully begin in the near future."

**From the Original Email:**
> "These findings do not mean people should take lithium supplements to prevent dementia. The research is early, and lithium (even in low doses) can affect kidney and thyroid function. Any use should be discussed with a clinician."

### Why Wait?

| Reason | Details |
| ------ | ------- |
| **Dosing unclear** | The ~5mg dose mentioned in supplements is arbitrary, not evidence-based |
| **Form matters** | Most supplements are not pharmaceutical-grade |
| **Drug interactions** | Lithium interacts with Losartan and other medications |
| **Monitoring needed** | Kidney and thyroid function should be checked |
| **No regulatory oversight** | Supplements are unregulated; purity varies |

---

## Comparison: Lithium vs. New AD Drugs

| Factor | Lithium | Lecanemab/Donanemab |
| ------ | ------- | ------------------- |
| **Cost** | ~$100/year | ~$26,000-32,000/year |
| **Administration** | Oral pill | IV infusion |
| **Safety profile** | Well-characterized (60+ years of use) | ARIA risk (brain swelling/bleeding) |
| **Efficacy** | Comparable or better (meta-analysis) | FDA approved |
| **Evidence for AD** | Phase 2 level | Phase 3 |

---

## Evidence Confidence Levels

| Claim | Confidence | Basis |
| ----- | ---------- | ----- |
| Lithium is neuroprotective | **HIGH** | Multiple RCTs + mechanisms |
| Low brain lithium linked to AD | **HIGH** | Nature 2025 study |
| Lithium orotate works better than carbonate | **MODERATE** | Mouse studies only |
| Lithium can prevent dementia | **MODERATE** | Epidemiological + small trials |
| Lithium is ready for clinical use | **LOW** | No Phase 3 trials |

---

## What to Watch For

1. **Harvard/Yankner Clinical Trial**: A human trial of lithium orotate is being planned
2. **LATTICE Trial Results**: University of Pittsburgh trial (80 participants, 2 years) results are pending
3. **Biomarker studies**: p-tau217 blood tests may enable surrogate endpoint trials

---

## For Healthcare Providers

### If Patients Ask About Lithium for AD Prevention

1. **Acknowledge** the promising research
2. **Explain** that clinical trials are needed before recommendations
3. **Discuss** risks: kidney function, thyroid function, dehydration, drug interactions
4. **Note** that lithium carbonate (the form with safety data) may not be the optimal form
5. **Consider** monitoring patients who choose to try supplements anyway—baseline and periodic kidney/thyroid function
6. **Document** the shared decision-making conversation

### Current Evidence-Based Uses of Lithium

- Bipolar disorder (FDA approved)
- Suicide prevention (evidence-based)
- Augmentation for treatment-resistant depression

---

## Sources

All findings in this summary are based on peer-reviewed literature indexed in PubMed:

1. **Aron L et al.** Lithium deficiency and the onset of Alzheimer's disease. *Nature*. 2025;645:712-721. PMID: 40770094
2. **Kessing LV et al.** Association of Lithium in Drinking Water With the Incidence of Dementia. *JAMA Psychiatry*. 2017;74(10):1005-1010. PMID: 28832877
3. **Forlenza OV et al.** Clinical and biological effects of long-term lithium treatment in older adults with amnestic MCI. *Br J Psychiatry*. 2019;215(5):668-674. PMID: 30947755
4. **Terao I & Kodama W.** Comparative efficacy of donanemab, lecanemab, aducanumab and lithium. *Ageing Res Rev*. 2024;94:102203. PMID: 38253184
5. **Matsunaga S et al.** Lithium as a Treatment for AD: A Systematic Review and Meta-Analysis. *J Alzheimers Dis*. 2015;48(2):403-10. PMID: 26402004

---

*Document prepared for informational purposes. Not medical advice.*
*Last Updated: February 5, 2026*
